Funding infectious disease research: a systematic analysis of UK research investments by funders 1997-2010.
Funding infectious disease research: a systematic analysis of UK research investments by funders 1997-2010.
复制标题
DOI：
10.1371/journal.pone.0105722
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Atun R
中科院分区：
文献类型：
--
作者：
Fitchett JR;Head MG;Cooke MK;Wurie FB;Atun R
研究投资对于解决疾病负担至关重要，但有限资源的分配却缺乏记录。我们系统地审查了资助组织向英国机构及其全球合作伙伴进行传染病研究的投资。 1997年至2010年期间的公共和慈善投资也包括在内。我们按照传染病、跨领域主题以及研发价值链对研究进行了分类，反映了科学类型。我们确定了 6165 项资助研究，研究总投资为 26 亿英镑。公共组织提供了 14 亿英镑（54.0%）的投资，而慈善组织提供了 11 亿英镑（42.4%）的投资。全球健康研究投资达 9.28 亿英镑（35.7%）。威康信托 (Wellcome Trust) 是领先投资者，投资额为 6.88 亿英镑 (26.5%)，紧随其后的是英国医学研究委员会 (MRC)，投资额为 6.73 亿英镑 (25.9%)。随着时间的推移，资金波动很大，慈善组织的资金每年约为 4000 万英镑至 1.6 亿英镑，公共资助者的资金每年约为 3000 万英镑至 2.3 亿英镑。传染病研究经费需要全球协调和战略性长期愿景。我们的分析表明投资模式的多样性和不一致，年度资金金额波动较大，产品开发和临床试验的投资有限。
Research investments are essential to address the burden of disease, however allocation of limited resources is poorly documented. We systematically reviewed the investments awarded by funding organisations to UK institutions and their global partners for infectious disease research. Public and philanthropic investments for the period 1997 to 2010 were included. We categorised studies by infectious disease, cross-cutting theme, and by research and development value chain, reflecting the type of science. We identified 6165 funded studies, with a total research investment of UK £2.6 billion. Public organisations provided £1.4 billion (54.0%) of investments compared with £1.1 billion (42.4%) by philanthropic organisations. Global health studies represented an investment of £928 million (35.7%). The Wellcome Trust was the leading investor with £688 million (26.5%), closely followed by the UK Medical Research Council (MRC) with £673 million (25.9%). Funding over time was volatile, ranging from ∼£40 million to ∼£160 million per year for philanthropic organisations and ∼£30 million to ∼£230 million for public funders. Infectious disease research funding requires global coordination and strategic long-term vision. Our analysis demonstrates the diversity and inconsistent patterns in investment, with volatility in annual funding amounts and limited investment for product development and clinical trials.
登录
查看更多内容
DOI：
10.2471/blt.07.045096
发表时间：
2008-01-01
期刊：
Bulletin of the World Health Organization: International Journal of Public Health
影响因子：
--
作者：
Wolfson, Lara J;Gasse, François;Okwo-Bele, Jean-Marie
通讯作者：
Okwo-Bele, Jean-Marie
影响因子：
120.7
作者：
Dorsey, E. Ray;de Roulet, Jason;Moses, Hamilton, III
通讯作者：
Moses, Hamilton, III
影响因子：
158.5
作者：
Gross, CP;Anderson, GF;Rowe, NR
通讯作者：
Rowe, NR
影响因子：
168.9
作者：
Atun, Rifat;Marie Knaul, Felicia;Frenk, Julio
通讯作者：
Frenk, Julio
影响因子：
15.8
作者：
Cobelens F;van Kampen S;Ochodo E;Atun R;Lienhardt C
通讯作者：
Lienhardt C